Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).
Fabrice André(Inserm), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Sherene Loi(The University of Melbourne), Gargi Patel(AstraZeneca (United Kingdom)), Carey K. Anders(Duke University), Joohyuk Sohn(Yonsei University), Peter Schmid, Pia Herbolsheimer(AstraZeneca (Finland)), Magdalena Wrona, Ling‐Ming Tseng(National Yang Ming Chiao Tung University), Adam Konpa(AstraZeneca (Poland)), Seock‐Ah Im(Seoul National University), Sarice Boston(AstraZeneca (Finland)), Annie Darilay(AstraZeneca (Finland)), Tinghui Yu(AstraZeneca (Finland)), Erika Hamilton(Sarah Cannon)
Cited by 25
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k